caa a22 4500 469026553 CHVBK 20180323132731.0 cr unu---uuuuu 170328e19920801xx s 000 0 eng 10.1007/BF01962546 doi (NATIONALLICENCE)springer-10.1007/BF01962546 Takx-Köhlen B. Department of Clinical Pharmacy and Toxicology, University Hospital of Maastricht, P.O. Box 5800, 6202, AZ Maastricht, the Netherlands aut Immunomodulators [Elektronische Daten] Future prospects [B. Takx-Köhlen] The future role of the immunomodulators in medical practice is yet to be defined. The key question is whether these new substances will bring remarkable progress in transplantation or in the treatment of such conditions as cancer, AIDS, and autoimmune diseases, or whether they will be of only minor adjunctive importance. As background to the discussion of immunomodulating agents, the immune system is explained, with emphasis on the roles of T and B lymphocytes, macrophages, phagocytes, human leukocyte antigen and the complement system. Special attention is given to the cytokines, particularly the lymphokines. The immunomodulators can be divided into three main groups: immunosuppressive agents, such as FK 506 and rapamycin; immunostimulating agents, of which BCG vaccine is most important; and the remaining immunomodulators, which include the biological response modifiers.The last group, which encompasses the colony-stimulating factors (GM-CSF, G-CSF, and M-CSF), the interleukins, the interferons, and the tumour necrosis factors, is described in detail. Innovative research and medical applications of these cytokines, including indications, contraindications, and adverse reactions, are discussed. The role of monoclonal antibodies against endotoxins is also described. Royal Dutch Association for Advancement of Pharmacy, 1992 Cytokines nationallicence Haematopoietic growth factors nationallicence Immunomodulators nationallicence Interferons nationallicence Interleukins nationallicence Lymphocytes nationallicence Lymphokines nationallicence Monoclonal antibodies nationallicence Tumor necrosis factors nationallicence Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 245-252 0031-6911 14:4<245 1992 14 11096 https://doi.org/10.1007/BF01962546 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01962546 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Takx-Köhlen B. Department of Clinical Pharmacy and Toxicology, University Hospital of Maastricht, P.O. Box 5800, 6202, AZ Maastricht, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/4(1992-08-01), 245-252 0031-6911 14:4<245 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer